Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01995123 · ClinicalTrials.gov registry record · NA
Behavioral Activation for Smoking Cessation in PTSD
A NA study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 124
- Enrollment target
NCT01995123: Completed NA study, sponsored by VA Office of Research and Development.
NCT01995123 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 124 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01995123, a NA study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to examine whether behavioral activation as an adjuvant to standard smoking cessation treatment improves smoking cessation outcomes among veterans with PTSD relative to a comparably intense combination of standard smoking cessation treatment + health and smoking education. It is expected that behavioral activation will produce more successful results than health and smoking education when paired with standard smoking cessation treatment.
Primary Outcome
7-day point prevalence abstinence at weeks 4, 12, 20, and 26 post target quit day
Interventions
- BEHAVIORAL Behavioral Activation Therapy
- BEHAVIORAL Health and Smoking Education
- BEHAVIORAL Standard Smoking Cessation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2014-09-08 |
| Est. Completion | 2019-03-29 |
| Phase | NA |
What the finished NCT01995123 record still lists
NCT01995123 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Behavioral Activation Therapy is the first listed.
NCT01995123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01995123 about?
NCT01995123 is a clinical study titled "Behavioral Activation for Smoking Cessation in PTSD". The purpose of this study is to examine whether behavioral activation as an adjuvant to standard smoking cessation treatment improves smoking cessation outcomes among veterans with PTSD relative to a comparably intense combination of standard smoking cessation treatment + health and smoking educatio...
What is the current status of trial NCT01995123?
This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2014-09-08. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT01995123?
The interventions under investigation include: Behavioral Activation Therapy (BEHAVIORAL), Health and Smoking Education (BEHAVIORAL), Standard Smoking Cessation Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT01995123?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01995123's enrollment target sits among peer trials
124 758th of 2000 higher than 1,239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI